Milnacipran for Migraine (uncommon preventive drug series)

Milnacipran for Migraine (uncommon preventive drug series)

Cerebral Torque

Click for the full list of the 50 uncommon migraine preventives

What is Milnacipran?

Milnacipran is a serotonin-norepinephrine reuptake inhibitor (SNRI). Therefore, it inhibits the reuptake of serotonin and norepinephrine.  

Milnacipran is a prescription medication that is FDA-approved to treat fibromyalgia. It is also used off-label, at times, for the treatment of major depressive disorder (MDD) and migraine.

How Does Milnacipran Work?

Milnacipran works by inhibiting the reuptake of serotonin and norepinephrine. By increasing the concentration of these two neurotransmitters that are involved in pain and mood regulation, milnacipran may help to reduce pain and improve mood. 

Milnacipran as a Potential Treatment Option for Migraine

As stated earlier, milnacipran is not approved by the FDA for the treatment of migraine, but it is still prescribed off-label for chronic, refractory cases at the discretion of the prescribing physician. It may also be beneficial for those with concomitant fibromyalgia and migraine.

In one study published in the Journal of Pain, milnacipran was effective in reducing pain in individuals with chronic migraine and comorbid fibromyalgia. It is important to note that its effects on migraine alone were not studied.

Source: https://www.jpain.org/article/S1526-5900(10)00090-8/fulltext

In another prospective cohort, open-label study, milnacipran was associated with a significant reduction in headache and migraine frequency, especially in those with episodic migraine.

Source: https://link.springer.com/article/10.1007/s10072-013-1536-0

More studies need to be done as the evidence is still scarce.

Potential Side Effects of Milnacipran

Common side effects of milnacipran include nausea, headache, dry mouth, insomnia, and constipation. If you experience any severe side effects or have concerns about taking this medication, it is important to speak with your healthcare provider.

Other Considerations for Milnacipran

Do not use milnacipran if you have used an MAO inhibitor in the past 14 days.

Risk of serotonin syndrome if used with triptans, but unlikely. Speak to your healthcare provider.

This is a cursory understanding of uncommon migraine medications. This is only to be used as a resource to go to your neurologist with. 

Back to blog
  • My 6 Favorite HeadaTerm 2 Features

    My 6 Favorite HeadaTerm 2 Features

    Cerebral Torque

    HeadaTerm 2: FDA-Cleared Migraine Relief for less than $80 Use code: CEREBRALTORQUE for 20% OFF! Get HeadaTerm 2 Now Your browser does not support the video tag. Uses the same eTNS technology...

    My 6 Favorite HeadaTerm 2 Features

    Cerebral Torque

    HeadaTerm 2: FDA-Cleared Migraine Relief for less than $80 Use code: CEREBRALTORQUE for 20% OFF! Get HeadaTerm 2 Now Your browser does not support the video tag. Uses the same eTNS technology...

  • The Two Migraine Pathophysiology Theories

    Cerebral Torque

    Migraine Pathophysiology Theories

    The Two Migraine Pathophysiology Theories

    Cerebral Torque

    Migraine Pathophysiology Theories

  • Cortical Spreading Depression Video Study Guide

    Cortical Spreading Depression Video Study Guide

    Cerebral Torque

    (Scroll down for video) Important Concepts: Definition of Cortical Spreading Depression (CSD): A wave of neuronal and glial depolarization that slowly progresses across the cerebral cortex. Role in Migraine: CSD...

    Cortical Spreading Depression Video Study Guide

    Cerebral Torque

    (Scroll down for video) Important Concepts: Definition of Cortical Spreading Depression (CSD): A wave of neuronal and glial depolarization that slowly progresses across the cerebral cortex. Role in Migraine: CSD...

  • A Breakthrough on the Horizon: PACAP-Targeting Antibodies Offer New Promise for Migraine Prevention

    A Breakthrough on the Horizon: PACAP-Targeting ...

    Cerebral Torque

    Migraine patients may soon have a new treatment option. Recent clinical trials show promising results for Lu AG09222, a monoclonal antibody targeting PACAP, a neuropeptide involved in migraine pathophysiology.

    A Breakthrough on the Horizon: PACAP-Targeting ...

    Cerebral Torque

    Migraine patients may soon have a new treatment option. Recent clinical trials show promising results for Lu AG09222, a monoclonal antibody targeting PACAP, a neuropeptide involved in migraine pathophysiology.

1 of 4